Company Profile
Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The Company’s lead drug candidate, AT-007, is a novel central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of CNS rare metabolic diseases, including Galactosemia, SORD Deficiency, and PMM2-CDG. The Company is also developing AT-001, a novel potent ARI, for the treatment of Diabetic Cardiomyopathy, or DbCM, a fatal fibrosis of the heart. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of Diabetic Retinopathy.
Latest Quarterly Earnings
Press Releases
Mar 01, 2023
Feb 16, 2023
Feb 09, 2023
View All - News
Events
Mar 8, 2023 at 2:10 PM EST
Feb 16, 2023 at 2:20 PM EST
Feb 16, 2023 at 8:30 AM EST
View All - Events
Presentations